Successful Treatment of Aplastic Anemia in the Kyrgyz Republic

AUTOIMMUNE THROMBOCYTOPENIA

SM Mamatov, EM Sadabaev, OA Dzhakypbaev, MO Eralieva

IK Akhunbaev Kyrgyz State Medical Academy, 92 Akhunbaev str., Bishkek, Kyrgyz Republic, 720020

For correspondence: Sagynali Murzaevich Mamatov, 92 Akhunbaev str., Bishkek, Kyrgyz Republic, 720020; Tel.: 996(555)48-00-77; е-mail: s.480077@mail.ru

For citation: Mamatov SM, Sadabaev EM, Dzhakypbaev OA, Eralieva MO. Successful Treatment of Aplastic Anemia in the Kyrgyz Republic. Clinical oncohematology. 2020;13(4):406–10. (In Russ).

DOI: 10.21320/2500-2139-2020-13-4-406-410

ABSTRACT

Aim. To assess the outcomes of combined immunosuppressive therapy in patients with severe aplastic anemia (АА) reflecting the first experience with the use of antithymocyte globulin and cyclosporine A at the National Center of Oncology and Hematology of Kyrgyz Republic Ministry of Health.

Materials & Methods. The trial included 24 AA patients (14 men and 10 women) aged 18–70 years. All patients received combined immunosuppressive therapy at the Hematology Department of the National Center of Oncology and Hematology of Kyrgyz Republic Ministry of Health (Bishkek).

Results. Initially the effect of immunosuppressive therapy was observed in 15 (62.5 %) out of 24 AA patients, 9 (37.5 %) patients did not respond to it. In 12 months after the start of combined immunosuppressive therapy the effect of it was reported in 18 (75 %) patients, 6 (25 %) patients showed no effect. The outcomes of combined immunosuppressive therapy in our study were independent of the age of patients and severity of the disease.

Conclusion. The first experience with the use of combined immunosuppressive therapy in patients with severe AA proved to be highly successful in terms of its efficacy. Immunosuppressive therapy comes first when allogeneic hematopoietic stem cell transplantation from a relative donor is not possible. Combined immunosuppressive therapy started immediately after AA diagnosis gives hope for achieving stable remission and blood components (erythrocytes, thrombocytes) transfusion independence.

Keywords: aplastic anemia, combined immunosuppressive therapy, antithymocyte globulin, cyclosporine A.

Received: May 15, 2020

Accepted: September 3, 2020

Read in PDF

REFERENCES

  1. Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–56. doi: 10.1056/NEJMra1413485.

  2. Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518–23. doi: 10.3324/haematol.12020.

  3. Bacigalupo How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–36. doi: 10.1182/blood-2016-08-693481.

  4. Scheinberg Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program. 2012;2012(1):292–300. doi: 10.1182/asheducation.v2012.1.292.3798310.

  5. Feng X, Scheinberg P, Biancotto A, et al. In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica. 2014;99(9):1433–40. doi: 10.3324/haematol.2014.106542.

  6. Camitta BM, Rozman C, Marin P, et al. Criteria for severe aplastic anaemia. Lancet. 1988;331(8580):303–4. doi: 10.1016/s0140-6736(88)90388-1.

  7. Михайлова Е.А., Паровичникова Е.Н., Кулагин А.Д. и др. Клинические рекомендации по лечению апластической анемии (комбинированная иммуносупрессивная терапия). М., 2018. 18 с. [Mikhailova EA, Parovichnikova EN, Kulagin AD, et al. Klinicheskie rekomendatsii po lecheniyu aplasticheskoi anemii (kombinirovannaya immunosupressivnaya terapiya). (Clinical guidelines for aplastic anemia treatment (combined immunosuppressive therapy).) Moscow; 2018. 18 р. (In Russ)]

  8. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43–70. doi: 1111/j.1365-2141.2009.07842.x.

  9. Scheinberg P, Rios O, Scheinberg P, et al. Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia. Am J Hematol. 2014;89(6):571–4. doi: 1002/ajh.23692.

  10. Михайлова Е.А., Фидарова З.Т., Устинова Е.Н. и др. Комбинированная иммуносупрессивная терапия больных апластической анемией: эффективность повторных курсов антитимоцитарного глобулина. Гематология и трансфузиология. 2014;59(4):11–8. [Mikhailova EA, Fidarova ZT, Ustinova EN, et al. Combined immunosuppressive therapy of aplastic anemia: efficacy of repeated courses of antithymocyte globulin. Gematologiya i transfuziologiya. 2014;59(4):11–8. (In Russ)]

  11. Peinemann F, Labeit AM. Stem cell transplantation of matched sibling donors compared with immunosuppressive therapy for acquired severe aplastic anaemia: a Cochrane systematic review. BMJ Open.2014;4(7):e005039. doi: 1136/bmjopen-2014-005039.

  12. Михайлова Е.А., Савченко В.Г. Спленэктомия в программной терапии апластической анемии. Терапевтический архив. 2006;8:52–7. [Mikhailova EA, Savchenko VG. Splenectomy in programmed therapy of aplastic anemia. Terapevticheskii arkhiv. 2006;8:52–7. (In Russ)]